RZL-012 for Dercum's Disease Lipomas
Dercum's Disease LipomasThirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With...
Dercum DiseaseLipedemaThis is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above the knee or women and men with nodular Dercum's disease. Each cohort will have 6 subjects who will receive RZL-012.
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas...
Dercum's DiseaseThis Phase 2 study will be an open-label and randomized study to assess the efficacy and safety of CBL-514 in participants with Dercum's Disease lipomas.
Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's...
LipedemaDercum DiseaseLipedema and Dercum's disease are known as Rare Adipose Disorders; they are painful, progressive disorders that result in abnormal accumulations of fat in the form of lipomas, excess lymphatic fluid, and many other symptoms. This trial aims to study RZL-012, a novel compound, in treating lipedema and Dercum's disease by triggering lipolysis at selected sites and reducing fat bringing pain relief and improvement in quality of life.
Insight Into Subcutaneous Adipose Tissue Disorders
LipedemaDercum's Disease2 moreThe INSIGHT study aims to phenotype individuals with subcutaneous adipose tissue (SAT) disorders specifically lipedema and Dercum's disease with an aim to find a cure for the SAT in these disorders that is resistant to diet and exercise.
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
LymphedemaLymphatic Disorders4 moreThe purpose of this study is to demonstrate the feasibility of near-infrared fluorescence imaging in subjects with acquired or hereditary lymphedema, in subjects with lipidema and other lymphovascular disorders and in normal health subjects; in order to attempt to correlate imaging phenotype(s) with genotype(s).